Literature DB >> 26170577

Pulmonary calcification in renal failure patient incidentally revealed by bone scintigraphy.

Ali Sellem1, Wassim El Ajmi1, Yazid Mahjoub1, Hatem Hammami1.   

Abstract

Pulmonary calcification is a subdiagnosed metabolic lung disease that is commonly asymptomatic and frequently associated with end-stage renal disease. We report a case of a 21-year-old man with a 4-year history of end-stage renal disease without respiratory symptoms. We discover incidentally on a bone scan a pulmonary calcification. Parathyroidectomy was refused by the patient. After 3 months of medical treatment, a second bone scan was done, and we found a partial response.

Entities:  

Keywords:  Bone scintigraphy; hemodialysis; lung calcification

Year:  2015        PMID: 26170577      PMCID: PMC4479923          DOI: 10.4103/0972-3919.158546

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


INTRODUCTION

Pulmonary calcification, typically asymptomatic, can be caused by a number of diseases, most common being end-stage renal disease. We describe a case of pulmonary calcifications associated with chronic kidney failure, which has been improved by medical treatment.

CASE REPORT

A 21-year-old man with a 4-year history of end-stage renal disease, on hemodialysis (three 4-h sessions/week), secondary to untreated bilateral vesico-ureteral reflux and neurogenic reactive bladder. The patient was referred for a bone scan because of osteoarticular complaints, especially at the elbows with limited mobility, and he reported mild and nonspecific symptoms, especially no significant dyspnea. Patient had high creatinine (428 μmol/l); serum phosphorus (4.51 mmol/l); total alkaline phosphatase, 108 U/L and serum parathyroid hormone level was 1700 pg/mL. Whole body bone scintigraphy images [Figure 1], showed a diffuse uptake in both lungs, more intense in the right one, suggesting an extra-osseous pulmonary calcification and an increased radiotracer uptake in the soft tissues of the left arm and in the periarticular soft tissues surrounding the elbows. The chest X-ray was normal [Figure 2].
Figure 1

Whole body bone scintigraphy with anterior and posterior projection performed 2 h after the injection of 18 mCi (666 MBq) of 99mTc-methylene diphosphonate which showed a diffuse uptake in both lungs and an increased radiotracer uptake in the soft tissues of the left arm and in the periarticular soft tissues surrounding the elbows (the hand positions are due to the limited mobility of the elbows)

Figure 2

Chest radiograph performed in the light of the data of bone scan

Whole body bone scintigraphy with anterior and posterior projection performed 2 h after the injection of 18 mCi (666 MBq) of 99mTc-methylene diphosphonate which showed a diffuse uptake in both lungs and an increased radiotracer uptake in the soft tissues of the left arm and in the periarticular soft tissues surrounding the elbows (the hand positions are due to the limited mobility of the elbows) Chest radiograph performed in the light of the data of bone scan Parathyroidectomy was declined by the patient. The medical therapeutic was chosen with dietary phosphorus restriction, noncalcium phosphate binders, calcimimetics, optimal control of secondary hyperparathyroidism, and intensive hemodialysis with a low-calcium dialysate. Second bone scan was done 3 months later [Figure 3] revealed a significant decrease, without disappearance, in the lung's uptake.
Figure 3

Second whole body bone scintigraphy with anterior and posterior projection performed 2 h after the injection of 18 mCi (666 MBq) of 99mTc-methylene diphosphonate revealed a significant a decrease in the lungs uptake (the hand positions are due to the limited mobility of the elbows)

Second whole body bone scintigraphy with anterior and posterior projection performed 2 h after the injection of 18 mCi (666 MBq) of 99mTc-methylene diphosphonate revealed a significant a decrease in the lungs uptake (the hand positions are due to the limited mobility of the elbows)

DISCUSSION

Soft-tissue calcification is a well-known complication of chronic renal failure. Calcified deposits may involve a variety of tissues and organs. Uremic tumoral calcinosis predominates in periarticular soft tissues with preservation of the bone and joint structures.[1] Several cases of metastatic pulmonary calcification (MPC) have been reported.[2] The clinical symptoms of MPC are usually mild[3] that's why this pathology is rarely diagnosed[4] and patients with extensive calcification may be asymptomatic.[5] Chest X-ray findings in MPC are nonspecific[67] and they are frequently normal.[8] The diagnosis is confirmed by biopsy, but can be suspected by typical findings on a Tc-99m-methylene diphosphonate bone scan, which is a sensitive and specific method for diagnosing.[89] That why, some authors have recommended the use of bone scan in hemodialysis patients with pulmonary symptoms.[4] Lungs affected by MPC demonstrate increased uptake, generally symmetrical.[510] Four major predisposing factors may contribute to MPC in dialysis patients. First, chronic acidosis leaches calcium from bone. Second, intermittent alkalosis favors the deposition of calcium salts. Third, hyperparathyroidism tends to cause bone resorption and intracellular hypercalcemia. Finally, low glomerular filtration rate can cause hyperphosphatemia and an elevated calcium-phosphorus product.[8] For patients with hyperparathyroidism, correction of this condition may stop the progression of nonvisceral soft-tissue calcification.[11] Our patient declined parathyroidectomy and was treated medically with a significant regression of scintigraphic abnormalities.
  11 in total

Review 1.  Tumoral calcinosis regression after subtotal parathyroidectomy: a case presentation and review of the literature.

Authors:  A Thakur; O J Hines; V Thakur; H E Gordon
Journal:  Surgery       Date:  1999-07       Impact factor: 3.982

2.  Regarding metastatic pulmonary calcification in renal failure.

Authors:  S K Morcos
Journal:  Br J Radiol       Date:  2002-08       Impact factor: 3.039

3.  Unusual manifestations of metastatic pulmonary calcification: high-resolution CT and pathological findings.

Authors:  Edson Marchiori; Nestor L Müller; Arthur Soares Souza; Dante L Escuissato; Emerson L Gasparetto; Elza Maria F P de Cerqueira
Journal:  J Thorac Imaging       Date:  2005-05       Impact factor: 3.000

4.  Imaging of diffuse metastatic and dystrophic pulmonary calcification in children after haematopoietic stem cell transplantation.

Authors:  A Guermazi; H Espérou; F Selimi; E Gluckman
Journal:  Br J Radiol       Date:  2005-08       Impact factor: 3.039

5.  Metastatic pulmonary calcification in a dialysis patient: case report and a review.

Authors:  Christoph H Eggert; Robert C Albright
Journal:  Hemodial Int       Date:  2006-10       Impact factor: 1.812

6.  Fulminant pulmonary calciphylaxis and metastatic calcification causing acute respiratory failure in a uremic patient.

Authors:  Yi-Jung Li; Ya-Chung Tian; Yung-Chang Chen; Shiu-Feng Huang; Chung-Chi Huang; Ji-Tseng Fang; Chih-Wei Yang
Journal:  Am J Kidney Dis       Date:  2006-04       Impact factor: 8.860

7.  Uremic tumoral calcinosis in patients on peritoneal dialysis: clinical, radiologic, and laboratory features.

Authors:  Hung-Yi Chu; Pauling Chu; Yuh-Feng Lin; Heng-Kuang Chou; Shih-Hua Lin
Journal:  Perit Dial Int       Date:  2011-02-28       Impact factor: 1.756

8.  Case report: Rapidly progressive metastatic pulmonary calcification: evolution of changes on CT.

Authors:  P D Thurley; R Duerden; S Roe; K Pointon
Journal:  Br J Radiol       Date:  2009-08       Impact factor: 3.039

9.  Uptake of bone imaging agents by diffuse pulmonary metastatic calcification.

Authors:  D I Rosenthal; H L Chandler; F Azizi; P B Schneider
Journal:  AJR Am J Roentgenol       Date:  1977-11       Impact factor: 3.959

10.  Metastatic pulmonary calcification mimicking air-space disease. Technetium-99m-MDP SPECT imaging.

Authors:  F J Brodeur; E A Kazerooni
Journal:  Chest       Date:  1994-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.